Leerink analyst Geoffrey Porges downgraded Celgene (CELG) to Market Perform from Outperform after the company agreed to be acquired by Bristol-Myers (BMY), stating that “the best deal is sometimes the only deal.” He lowered his price target on Celgene shares to $102 from $112.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.